Tyrosine kinase inhibition and chemotherapy; [Tirozin kinaz i̇nhibisyonu ve kemoterapi]
| dc.contributor.author | Zeren T. | |
| dc.contributor.author | Ekerbiçer N. | |
| dc.date.accessioned | 2025-04-10T11:17:42Z | |
| dc.date.available | 2025-04-10T11:17:42Z | |
| dc.date.issued | 2004 | |
| dc.description.abstract | Breast cancer is the most common tumor in women and causes 18% of the cancer related deaths among women in the USA. The five year survival rate of metastatic breast cancer is only 18%. The treatment remains incurable with standard chemotherapy. Epidermal Growth Factor - Receptor (EGF-R) shows tyrosine kinase activity which has been suggested play an significant role on the cell proliferation. Many types of cancer, specially breast cancer, display enhanced EGF-R expression on cell surface membranes. EGF-Receptor may be a suitable target and the inhibitors of protein tyrosine kinases may be useful for therapy of metastatic breast cancer. Genistein (Gen) is a tyrosine kinase inhibitor. Recent studies demonstrated that the conjugation of EGF and Genistein (EGF-Gen) has a cytotoxic activity against breast cancer cells. The specific aim of this study is to examine the anti-tumor efficacy of EGF-Gen conjugate, side by side with standard chemotherapeutic agents (methotrexate, adriamycin, and cyclophosphamide) and the combine activity of EGF-Gen conjugate with standard chemotherapeutic agents in a SCID mouse xenograft model of human breast cancer. | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/52876 | |
| dc.title | Tyrosine kinase inhibition and chemotherapy; [Tirozin kinaz i̇nhibisyonu ve kemoterapi] | |
| dc.type | Article |